Monoclonal antibody therapy market information, by source (recombinant, chimeric, humanized, human, and other), by application (diagnostic test, analytical and chemical uses, cancer treatment, autoimmune diseases, hematological disorders, and others) by end users (hospitals, clinic, research laboratories and others) - Forecast to 2022

Market Synopsis of Monoclonal antibody therapy Market:

Market Scenario:
Monoclonal antibodies are laboratory-produced antibodies structured to be the substitute of natural antibodies which can enhance or mimic the immune system's attack on harmful cells. Monoclonal antibody therapy is a type of immunotherapy which requires monoclonal antibodies to bind specifically to certain type of cells and proteins which stimulates the immune system to attack those cells. Currently, it is possible to produce monoclonal antibodies specific to any extracellular target and research is being carried out to amplify the application scope of the monoclonal antibodies in different areas of medical science. Globally, the market for monoclonal antibody therapy is growing rapidly and it is expected to grow at the rate of about XX% from 2016 to 2022.

Key Finding

- The global monoclonal antibody therapy market is expected to reach $XX billion by 2022.
- Recombinant segment holds the largest share of XX% of this market.
- North America holds the largest market share of XX% of monoclonal antibody therapy market and is anticipated to reach $XX billion by the end of forecast period.
- Globally, Asia-Pacific is the fastest growing region and is expected to grow at the rate of XX% during the forecast period.

Study objectives of Monoclonal Antibody Therapy Market:

- To provide detail analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the monoclonal antibody therapy market
- To provide insights about factors affecting the market growth
- To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
- To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.
- To provide country level analysis of the market with respect to the current market size and future prospective
- To provide country level analysis of the market for segments by source, by application, by end user and its sub-segments.
To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.

To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global monoclonal antibody therapy market.

Monoclonal antibody therapy Market, by Region

Segments

Monoclonal antibody therapy market has been segmented on the basis of source which comprises of recombinant, chimeric, humanized, human, and other. On the basis of application, market is segmented into diagnostic test, analytical and chemical uses, cancer treatment, autoimmune diseases, hematological disorders, and others. On the basis of end users, market is segmented into hospitals, clinic, research laboratories and others.

Regional Analysis of Monoclonal Antibody Therapy Market

Globally North America is the largest market for monoclonal antibody therapy. Europe is the second-largest market. Furthermore Asia pacific market is expected to be the fastest growing market for monoclonal antibody therapy.

Key Players for Monoclonal Antibody Therapy Market

Some of the key players in this market are: AbbVie Inc., Amgen Inc., Bayer AG, Biogen Inc., Bristol – Myers Squibb Company, F. Hoffmann-La Roche Ltd., GenScript, GlaxoSmithKline Plc., Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, Sigma-Aldrich Co. LLC, and others.

The report for Monoclonal Antibody Therapy Market of Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insights of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.

Intended Audience

- Monoclonal antibody manufacturers and suppliers
- Contract Research Organizations (CROs)
- Research and Development (R&D) Companies
- Government Research Laboratories
Contents:

1 INTRODUCTION
   1.1 DEFINITION
   1.2 SCOPE OF STUDY
   1.2.1 RESEARCH OBJECTIVE
   1.2.2 ASSUMPTIONS & LIMITATIONS
   1.2.2.1 ASSUMPTIONS
   1.2.2.2 LIMITATIONS
   1.3 MARKET STRUCTURE

2 RESEARCH METHODOLOGY
   2.1 RESEARCH PROCESS:
   2.2 PRIMARY RESEARCH
   2.3 SECONDARY RESEARCH

3 MARKET DYNAMICS
   3.1 DRIVERS
   3.2 RESTRAINTS
   3.3 OPPORTUNITIES
   3.4 MACROECONOMIC INDICATORS

4 MARKET FACTOR ANALYSIS
   4.1 PORTERS FIVE FORCES MODEL
   4.2 BARGAINING POWER OF SUPPLIERS
   4.3 BARGAINING POWER OF BUYERS
   4.4 THREAT OF NEW ENTRANTS
   4.5 THREAT OF SUBSTITUTES
   4.6 INTENSITY OF RIVALRY

5 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY SOURCE
   5.1 RECOMBINANT
   5.2 CHIMERIC
   5.3 HUMANIZED
   5.4 HUMAN
   5.5 OTHER

6 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY APPLICATION
   6.1 DIAGNOSTIC TEST
   6.2 ANALYTICAL AND CHEMICAL USES
   6.3 CANCER TREATMENT
   6.4 AUTOIMMUNE DISEASES
   6.5 HEMATOLOGICAL DISORDERS
   6.6 OTHERS

7 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY END USER
   7.1 HOSPITALS
   7.2 CLINICS
   7.3 RESEARCH LABORATORIES
   7.4 OTHERS
8. GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY REGION

8.1 AMERICA
8.1.1 INTRODUCTION

8.2 EUROPE
8.2.1 INTRODUCTION

8.3 ASIA-PACIFIC
8.3.1 INTRODUCTION

8.4 MIDDLE EAST & AFRICA
8.4.1 INTRODUCTION

9 COMPETITIVE LANDSCAPE
9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
9.1.1 STRATEGIC PARTNERSHIP
9.1.2 MERGER & ACQUISITION

10 COMPANY PROFILE
10.1 ABBVIE INC.
10.1.1 OVERVIEW
10.1.2 PRODUCT OVERVIEW
10.1.3 FINANCIALS
10.1.4 KEY DEVELOPMENTS

10.2 AMGEN INC
10.2.1 OVERVIEW
10.2.2 PRODUCT OVERVIEW
10.2.3 FINANCIALS
10.2.4 KEY DEVELOPMENTS

10.3 GLAXOSMITHKLINE PLC
10.3.1 OVERVIEW
10.3.2 PRODUCT OVERVIEW
10.3.3 FINANCIALS
10.3.4 KEY DEVELOPMENT

10.4 MERCK KGAA
10.4.1 OVERVIEW
10.4.2 PRODUCT OVERVIEW
10.4.3 FINANCIALS
10.4.4 KEY DEVELOPMENTS

10.5 NOVARTIS AG
10.5.1 OVERVIEW
10.5.2 PRODUCT OVERVIEW
10.5.3 FINANCIALS
10.5.4 KEY DEVELOPMENTS

10.6 OTHERS

List of Tables
TABLE 1 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY SOURCE, 2013-2022 (USD MILLION)
TABLE 2 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY APPLICATION, 2013-2022 (USD MILLION)
TABLE 3 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY END USER, 2013-2022 (USD MILLION)
TABLE 4 GLOBAL MONOCLONAL ANTIBODY THERAPY MARKET, BY REGION, 2013-2022 (USD MILLION)

List of Figures
FIGURE 1 RESEARCH PROCESS